Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of glaxosmithkline HSV-2 glycoprotein D2 subunit vaccine

Journal of Infectious Diseases

Volumn 210, Issue 4, 2014, Pages 571-575

  Awasthi, Sita ^a   Belshe, Robert B ^b   Friedman, Harvey M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Glycoprotein C; Glycoprotein D; Glycoprotein E; Herpevac Trial; HSV 1; HSV 2; Neutralizing antibody; Vaccine

Indexed keywords

GLYCOPROTEIN D2 ANTIBODY; HERPES VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS NEUTRALIZATION; VIRUS STRAIN;

GLYCOPROTEIN C; GLYCOPROTEIN D; GLYCOPROTEIN E; HERPEVAC TRIAL; HSV-1; HSV-2; NEUTRALIZING ANTIBODY; VACCINE;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84905578748     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu177     Document Type: Article

References (14)

1. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366: 34-43.
2. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652-61.
3. Wald A. Genital HSV-1 infections. Sex Transm Infect 2006; 82: 189-90.
4. Whitbeck JC, Peng C, Lou H, et al. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol 1997; 71: 6083-93.
5. Belshe RB, Heineman TC, Bernstein DI, et al. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 2013.
6. Awasthi S, Lubinski JM, Shaw CE, et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 2011; 85: 10472-86.
7. Judson KA, Lubinski JM, Jiang M, et al. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J Virol 2003; 77: 12639-45.
8. Awasthi S, Lubinski JM, Friedman HM. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine 2009; 27: 6845-53.
9. Hook LM, Lubinski JM, Jiang M, Pangburn MK, Friedman HM. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody. J Virol 2006; 80: 4038-46.
10. Wang F, Tang W, McGraw HM, Bennett J, Enquist LW, Friedman HM. Herpes simplex virus type 1 glycoprotein E is required for axonal localization of capsid, tegument, and membrane glycoproteins. J Virol 2005; 79: 13362-72.
11. Wang F, Zumbrun EE, Huang J, Si H, Makaroun L, Friedman HM. Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons. Virology 2010; 405: 269-79.
12. Hook LM, Huang J, Jiang M, Hodinka R, Friedman HM. Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E. J Virol 2008; 82: 6935-41.
13. Handler CG, Eisenberg RJ, Cohen GH. Oligomeric structure of glycoproteins in herpes simplex virus type 1. J Virol 1996; 70: 6067-70.
14. Julien JP, Lee PS, Wilson IA. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev 2012; 250: 180-98.